EPEepsita Priyadarshini

Eepsita Priyadarshini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eepsita Priyadarshini has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting ESKAPE pathogens with ZnS and Au@ZnS Core–Shell nanoconjugates for improved biofilm control

    by Shaikh Imran Ibrahim, Ajith Manayil Parambil, Neha Jha, Anuj Kumar Tomar, Paulraj Rajamani, Xiao Jian, Eepsita Priyadarshini, Shao Chuxiao

    The escalating prevalence of antibiotic-resistant infections and implant-related complications caused by biofilm-forming pathogens from the ESKAPE group, as identified by the World Health Organization (WHO), underscores the urgent need for innovative anti-biofilm strategies. Their occurrence on medical implants & prosthetic devices, as well as nosocomial infections in co-morbid patients, has become a global concern in the healthcare sector. In response, we investigated the efficacy of as-synthesized ZnS quantum dots (ZnS QD) and novel Au@ZnS nanoconjugates (Au@ZnS NC) against a spectrum of ESKAPE pathogens. The present study aimed to elucidate their antibacterial and anti-biofilm efficacy, focusing on Acinetobacter baumannii, Enterobacter cloacae, Staphylococcus epidermidis, Enterococcus faecium, Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus faecalis, Staphylococcus aureus and Enterobacter aerogenes pathogens. The novel synthesis and application of ZnS QD and Au@ZnS core-shell NC demonstrate exceptional anti-biofilm efficacy, stability, and solubility in aqueous environments. Utilizing minimum inhibitory concentration (MIC) assays, tube dilution, and biofilm formation assay, we noticed a significant reduction in biofilm formation and extracellular polymeric substances (EPS) production upon treatment with Au@ZnS NC, even at low concentrations. Further investigations, including cell permeability assay, reactive oxygen species analysis, and comet analysis, demonstrated that the Au@ZnS NC induced oxidative stress, destabilizing cell structure, macromolecule destruction, and DNA strand breakage. Notably, Au@ZnS nanoconjugates effectively inhibited biofilm formation within 24 h across all tested strains, outperforming ZnS quantum dots. This research highlights the potential of Au@ZnS nanoconjugates to revolutionize infection control on medical devices and implants, offering a promising solution to the global healthcare challenge posed by biofilm-forming pathogens as we also observed minimal bacterial colonization on Au@ZnS treated urinary catheters.


  • Multimode sensing of riboflavin via Ag@carbon dot conjugates

    by Eepsita Priyadarshini, Kamla Rawat, H. B. Bohidar


  • Open Access

    Quantum Dots-Based Nano-Coatings for Inhibition of Microbial Biofilms: A Mini Review

    by Eepsita Priyadarshini, Kamla Rawat, Himadri Bihari Bohidar

    Infection of implants by microbial biofilm is chiefly caused by Staphylococci, Pseudomonas and Candida species. The growth of microbes by forming biofilms offers them protection from antibiotics, drugs and host defense mechanisms. The eradication of biofilms from implants and medical devices is difficult because of the protection by the biofilm forming pathogenic microbes. Hence, researches are focused on development of antibiofilm materials, which are basically constituted of antimicrobial substances or antimicrobial coatings. Nanomaterial-based coatings offer a promising solution in this regard. Quantum dots (QDs) are the group of semiconductor nanoparticles with high photoluminescent properties compared to conventional organic fluorophores. Thus, drug-conjugated QDs can be a promising alternative for biofilm treatment, and these can serve as excellent alternatives for the mitigation of recalcitrant biomaterial-associated infections caused by resistant strains. Furthermore, their use as antibiofilm coating would avoid the dispersion of antimicrobial agents in the surrounding cells and tissues, thereby minimizing the risks of developing microbial resistivity.